Lapatinib potentiates cytotoxicity of YM155 in neuroblastoma via inhibition of the ABCB1 efflux transporter
Abstract Adverse side effects of cancer agents are of great concern in the context of childhood tumors where they can reduce the quality of life in young patients and cause life-long adverse effects. Synergistic drug combinations can lessen potential toxic side effects through lower dosing and simul...
Guardado en:
Autores principales: | Branka Radic-Sarikas, Melinda Halasz, Kilian V. M. Huber, Georg E. Winter, Kalliopi P. Tsafou, Theodore Papamarkou, Søren Brunak, Walter Kolch, Giulio Superti-Furga |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/69692b39268b4938b59ac45022e3640d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer.
por: J Robert McCorkle, et al.
Publicado: (2021) -
Early Cellular Responses of Prostate Carcinoma Cells to Sepantronium Bromide (YM155) Involve Suppression of mTORC1 by AMPK
por: David Danielpour, et al.
Publicado: (2019) -
Acta No. 155
por: Banco Central de Chile
Publicado: (2019) -
Clinical data mining reveals analgesic effects of lapatinib in cancer patients
por: Shuo Zhou, et al.
Publicado: (2021) -
Inhibition of PIKfyve by YM-201636 dysregulates autophagy and leads to apoptosis-independent neuronal cell death.
por: Sally Martin, et al.
Publicado: (2013)